M. ROWE AND OTHERS
The existence of virus-infected B cells in healthy seropositive individuals is readily demonstrated by the ease with which spontaneously outgrowing lymphoblastoid cell lines (LCLs) can be established from cultures of circulating lymphocytes. These LCLs have an unlimited growth capacity in vitro, and each cell within a line carries EBV DNA. Generally, LCLs are not usually permissive for EBV replication; proteins of the early and late phases of the lytic cycle may be detected in fewer than 5 ~, if any, of the cell population. An invariable viral fingerprint of all infected LCLs is the presence of the EBV-determined nuclear antigen (EBNA) as originally defined by anti-complement immunofluorescence (ACIF) with appropriate human sera (Reedman & Klein, 1973) . Recent studies have shown that there are at least six EBNAs, each encoded by a different part of the viral DNA, which are expressed by every cell of an LCL. Furthermore, at least one membrane protein (the latent membrane protein, LMP) is regularly expressed in these cells. The latent EBV proteins so far identified in LCLs are summarized in Table 1 .
All of the EBNAs, with the exception of EBNA 5, were first identified with appropriate human sera and were subsequently mapped to the viral genome. EBNA 5 was originally identified using rabbit antisera raised to a synthetic peptide corresponding to part of the predicted protein sequence , and EBNA 5-reactive human sera have since been reported (Finke et al., 1987; Rowe et al., 1987; Wang et al., 1987) . LMP was first identified using antibodies raised experimentally to a fusion protein containing the carboxy half of the predicted LMP protein (Hennessy et al., 1984; Mann et al., 1985) . The existence of human antibodies to LMP in healthy individuals remains to be demonstrated. However, studies using the leukocyte migration inhibition (LMI) assay (Szigeti et al., 1984) , together with other studies using ELISAs incorporating short synthetic peptides corresponding to LMP amino acid sequences (Modrow & Wolf, 1986; Dillner et al., 1987) , indicated that a humoral response to LMP may be mounted in patients with BL or NPC.
Serology, in particular the antibody responses to the early antigen and the viral capsid antigen (VCA) complexes, has played an important part in defining the association of EBV with IM, BL and NPC. Studies on the antibody response to the transformation-associated viral antigens in certain patients suggest that a weak or undetectable antibody response to EBNA in ACIF tests is associated with defective T cell function (Berkel et aL, 1979; Masucci et aL, 1981 ; Vilmer et al., 1984) . Following the realization that EBNA consists of at least six distinct proteins, much of the earlier EBNA serology needs to be repeated to establish whether antibody responses to any particular EBNA may be of diagnostic or prognostic value. To this end, recent studies using cells transfected with and expressing single EBV genes as targets for ACIF tests have defined more precisely the antibody responses to EBNA 1 and EBNA 2 in healthy individuals and in patients with BL, NPC, rheumatoid arthritis (RA), IM and human immunodeficiency virus infections Seigneurin et al., 1987) . Further studies have been hampered by the lack of available transfected cells expressing appropriately high levels of each of the remaining four known EBNAs. We have therefore taken a different approach, which has enabled us to investigate the antibody responses to all of the known growth transformation-associated EBV proteins, including LMP.
A combination of immunoblotting and immunoprecipitation techniques was employed to detect specific antibodies reacting with well characterized extracts of EBV-positive cells. We report here the humoral response to each of the latent EBV proteins in healthy individuals and in the two malignancies in which EBV is a causal agent, BL and NPC. Patients with RA were also studied because an'increased antibody response to EBNA 2 has been reported in EBV-immune cases of this disease (Sculley et al., 1986; Seigneurin et al., 1987) .
METHODS
Human sera. Control sera were obtained from 37 healthy laboratory personnel, 10 of whom were known, from immunofluorescence tests, to be seronegative for VCA. Patient sera, all EBV-seropositive, were obtained in the course of previous collaborative studies from Dr P. Clifford (Kenyatta National Hospital, Nairobi, Kenya), Dr T. Tursz (Institut Gustave Roussy, Villejuif, France), Dr W. Henle (Joseph Stokes Jr Research Institute, Philadelphia, Pa., U.S.A.), and Dr E. Nilsson (Department of Rheumatology, Karolinska Institute). The 25 BLpositive sera were all collected from African patients within 'high incidence' regions of East Africa. The NPCpositive sera were from 33 African and French patients with undifferentiated carcinoma of the post-nasal space.
Other sera included 21 from Swedish patients with RA, nine from healthy homosexuals, 10 from patients with AIDS, nine from patients with persistent generalized lymphadenopathy (PGL), and seven from patients with Kaposi's sarcoma.
Immunoblotting. Cells used as the source of protein samples in immunoblotting assays were fed 24 h prior to harvesting. The cells were washed once in phosphate-buffered saline (PBS), solubilized by sonication in sample buffer (50 mM-Tris-HCl pH 6-8, 49/o w/v SDS, 2% v/v 2-mercaptoethanol, 10% v/v glycerol, 0-01% bromophenol blue) at 107 cells/rot, and boiled for 3 rain. Samples were loaded onto a discontinuous polyacrytamide gel (13 cm wide) (Laemmli, 1970) consisting of a 3 ~ stacking gel and a 7.5 % resolving gel. When a 15-~vell stacking gel was used, 100pl samples were applied to each well, and when an open stacking gel was used for "strip blot' experiments, a 2.5 ml sample was applied per gel. The electrophoretically resolved protein samples were transferred to nitrocellulose filters in a Bio-Rad transfer apparatus at a constant 80 V for 5 b with water cooling. The nitrocellulose filters were stained with Ponceau S (Sigma) to note the position of Mr markers (SDS-6H; Sigma) run alongside the cell extracts, and excess protein-binding sites on the filters were then blocked by incubation in PBS containing 5 ~ non-fat dried milk (PBS-milk). For strip blot experiments, each filter was cut into 25 identical vertical strips which were placed in individual troughs of a Bio-Rad incubation tray. Subsequent incubations with diluted sera and detection of specific reactivities using alkaline phosphatase-conjugated goat anti-human Ig second step reagent were performed as described elsewhere (Finke et aL, 1987) .
Immunoprecipitation and immunoblotting (IPIB) assay. The IB4 cell line, an LCL established from cord blood by infection with the B95.8 strain of EBV (King et al., 1980) , was used as the source of EBNA 5 and LMP for the IPIB assays. Washed cells were solubilized at 0 °C by sonication in RIPA buffer (50 mM-Tris-HC1 pH 7.5,400 mMNaC1, 5m~I-EDTA, 0.5~ sodium deoxycholate, 0.5% Nonidet P40, 0.1~SDS) at a concentration of 5 x 107 cells/ml. The lysate was pre-cleared by incubating for 1 h with Protein A-Sepharose beads (Pharmacia), and clarified by centrifugation. An equal volume of culture supernatant containing JF 186 monoclonal antibody (MAb) (anti-EBNA 5; Finke et al., 1987) was mixed with the cell lysate and immune complexes were allowed to form at 0 °C overnight. Immunoprecipitates of EBNA 5 were isolated on Protein A beads, which were then washed three times in RIPA buffer and once in PBS before boiling in the gel sample buffer. The spent cell lysate was immediately used for immunoprecipitation of LMP, in a manner similar to that described for EBNA 5 except that the LMP antibodies (CS. 1 to 4; Rowe et al., 1987 a) were first covalently immobilized to Protein A-Sepharose beads, to which rabbit anti-mouse antibodies had been pre-adsorbed, according to the method of Simianis & Lane (1985) . In this way, the contamination of the LMP preparation by both rabbit and mouse immunoglobulins was minimized. The EBNA 5 and LMP immunoprecipitates were applied to open stacking gels on top of 7.5~ resolving gels, and were separated electrophoretically and processed for strip blots as described above. The amount of EBNA 5 loaded onto each gel (13 cm wide) corresponded to material extracted from 5 x 107 cells, whereas the amount of LMP loaded onto similar gels corresponded to material extracted from 2 x 108 cells. When the strip blots were used to screen human sera for reactivity with the respective antigens, at least one strip per gel was reserved for immunodetection with the appropriate MAb for precise identification of the specific protein bands.
Purification of human anti-LMP antibodies. LMP immunoprecipitated from 4 x 108 IB4 cells was separated on a 7.5 ~ polyacrylamide gel and transferred to nitrocellulose as described above. The position of the LMP band was identified by immunostaining two thin vertical end strips of the filter with MAb and alkaline phosphataseconjugated second step reagent. During this time, the remaining nitrocellulose sheet was incubated with selected human serum diluted 1:20 in PBS-milk. After 5 h incubation with human serum, a 0.5 cm horizontal strip of nitrocellulose identified as containing the LMP band was cut out, washed extensively, and the bound human antibodies were eluted with diethylamine, pH 11, as described elsewhere (Finke et al., 1987) .
LMI and LMl-blocking tests. The direct agarose microdroplet LMI assay was carried out as detailed previously (Szigeti et al., 1984) , and the LMI-blocking test was performed according to the method described by Sulitzeanu et al. (1986) . Briefly, IgG fractions of the test sera were mixed with the antigen solution (Raji cell membranes, or LMP fusion protein) and incubated at 0 °C for 2 h. Lyophilized Staphylococci lg Sorbent (The Enzyme Center, Boston, Mass., U.S.A.) was then added and mixed for a further 30 rain at 0 °C before centrifugation to remove the bacteria. Finally, horse serum was added to the supernatant to a final concentration of 10% (v/v) and the samples were filtered through a 0.45 p.m Millipore filter before they were added to the agarose microdroplets in the LMI test. Percentage blocking was calculated according to the formula [(MIs -MI) × 100]/MI where MI and MIs are mean migration indices in the absence and presence of the human test serum. Blocking in excess of 30~ was arbitrarily scored as positive.
RESULTS

Antibodies to LMP
Preliminary experiments were performed in order to test whether antibodies to LMP could be detected in human sera using the immunoblotting technique. BJAB-LMP, an EBV-negative B lymphoma cell line which has been transfected with the LMP gene (M. Rowe 
* Baer et aL (1984) , unpublished data), was used as the source of LMP-positive cell extract. From these experiments, it was apparent that while antibodies to LMP could be detected in certain sera, specific antibodies to LMP were weak relative to antibodies to normal cellular proteins found in extracts of the LMP-negative parental B JAB line (data not shown). A more sensitive assay (the IPIB assay) was therefore developed. LMP was immunoprecipitated from the EBV-transformed LCL, IB4, using specific MAbs covalently immobilized on Protein A-Sepharose beads, and then used as the antigen for immunoblots. In such an assay, immunoprecipitated LMP from 2 x 108 cells was separated on a gel (13 cm wide), and the nitrocellulose filters were cut into 25 individual strips for testing 25 different sera. Thus, each nitrocellulose strip contained about 10 times more LMP than would normally be present in corresponding strips with whole-cell extracts, while at the same time other cellular and viral proteins were substantially depleted. The major contaminating proteins were mouse and rabbit immunoglobulins released from the immunoprecipitates, but this contamination was minimized by covalently cross-linking the antibodies to the Protein A-Sepharose beads. Fig. 1 shows the result of a typical LMP IPIB assay. The position of the p63 LMP band was located from the strip incubated with the anti-LMP MAbs. Of the six healthy sera shown (two EBV-seronegative, strips 1 and 2, and four EBV-seropositive, strips 3 to 6), two reacted with LMP. Strip 5 was weakly positive and was typical of the signal strength obtained with most LMP-reactive sera from healthy individuals, whereas strip 6 (donor ST) showed exceptionally strong reactivity. LMP-reactive sera from patients with NPC (strips 8 to 11), BL (strips 14 to 16) and RA (not shown in Fig. 1 ) generally gave a stronger anti-LMP signal than was typical for the positive sera of healthy donors.
The results obtained with 115 sera tested at a single dilution (1:20) are summarized in Table 2 . Antibodies to LMP were not detected in any of 10 EBV-seronegative sera, but were detected in 6/27 EBV-seropositive sera from healthy individuals. The majority (64 to 76~o) of EBVseropositive sera from patients with BL, NPC and RA demonstrated anti-LMP reactivity.
Confirmation that the IPIB assay specifically identified antibodies to LMP was obtained by eluting antibodies bound to the p63 band on nitrocellulose (as described in Methods), and using these antibodies to probe immunoblots of whole-cell extracts. Fig. 2 shows the results of such an experiment with antibodies purified from serum RA39. No reactivity was observed with B JAB, but LMP was specifically detected in BJAB-LMP and in the EBV-transformed LCL IB4. LMPspecific reactivity could not be identified reliably in immunoblots probed with crude RA39 serum (data not shown).
Since sera from some BL and NPC patients, but not those from healthy donors, have previously been shown to block LMP-induced LMI, we sought to correlate the results of the LMP IPIB assay with LMI-blocking. For this set of experiments, l 3 selected sera were titrated to endpoint detection in the IPIB assay. Blocking of Raji cell membrane-induced LMI was tested in parallel, but since titration of LMI-blocking is difficult and of dubious, value, each serum was scored as positive when t> 3 0~ blocking was obtained at a standard 1:400 dilution of serum. The results shown in Table 3 reveal a good, though not absolute, correlation between the two assays. One notable discrepancy was found with the serum from ST (see also Fig. 1, strip 6 ), which had a strong anti-LMP titre of I : 960 in the IPIB assay but which was repeatedly negative in the LMI-blocking assay. Additional sera were compared in the two assays without titration. The results of the LMI-blocking assay indicated the presence of antibodies to LMP in 0/8 healthy seronegative sera (mean percentage blocking of LMI + S.D., 14 + 7), 0/13 healthy seropositive sera (13 + 6), 9/13 BL sera (41 + 19) and 12/16 NPC sera (46 + 17). Concordant results were obtained with all but four of these 50 sera when tested in the IPIB assay. The four discordant results were obtained with sera from healthy EBV-immune donors, all of which scored negative by the LMI-blocking assay; three of these were weakly positive in the IPIB assay, and one (ST) was exceptionally strong in the IPIB assay (see Table 3 for results with three of these sera: GS, OR and ST).
T a b l e 3. Comparison of lPIB and LMI-blocking assays for detection of anti-LMP antibodies
Antibodies to the EBNAs Antibodies to EBNAs 1, 2, 3, 4 and 6 were identified by simple immunoblots using whole-cell extracts of selected, well characterized cell lines. Typical results obtained with a reference serum (PG, which contained antibodies to all six of the EBNAs and LMP) are shown in Fig. 3 . Note that the Mr of each of EBNAs 1, 2, 3, 4 and 6 varies from one cell line to another, but is characteristic for a given strain of EBV. EBNAs 1 and 2 are well characterized and easy to identify in most cell lines. In contrast, the high Mr group of EBNAs (EBNAs 3, 4 and 6) is less well characterized and, for the particular cell lines chosen for this study, the individual bands were identified using experimentally raised monospecific sera (Ricksten et al., 1988; M. Rowe, unpublished data) . Raji was not used for routine characterization of sera, but is shown here to illustrate the heterogeneity in this group of nuclear antigens among different virus strains; EBNA 6 is not expressed in Raji cells because there is a deletion in the viral D N A spanning the EBNA 6 gene (Polack et al., 1984; Ricksten et al., 1988) . The lines CBC-JK and CD-OBA were selected because of their unusually well separated and uniformly expressed high Mr EBNAs. Each serum was screened against an EBV-negative lymphoma line, B JAB or Louckes, in addition to the two EBV-positive LCLs mentioned above. Antibodies to EBNA 5 were not easily distinguished with the chosen cell lines and were therefore screened separately using an IPIB assay similar to that used for detection of antibodies to LMP. * Antibodies to EBNAs 1, 2, 3, 4 and 6 were detected by immunoblot of whole-cell extracts, while antibodies to EBNA 5 were detected by IPIB assay using EBNA 5 purified from the IB4 LCL.
t Sera were tested (a) at a 1:20 dilution and (b) at a 1:100 dilution. See Table 2 . § Nr, Not tested. When the antibody responses to each of the six EBNAs were determined for several sera, no characteristic differences were observed. For simplicity, therefore, the data are presented as cumulative figures for groups of sera rather than as results for each individual serum. Table 4 summarizes the EBNA serology of 112 different sera which were tested. Sera from healthy persons were compared with those from BL, NPC and RA. Most, but not all, sera were tested at two dilutions (1 : 20 and 1 : 100) to give some indication of the strength of the antibody response. Antibodies to EBNA 1 were regularly detected in all sera from EBV-positive individuals, regardless of disease group, when tested at 1 : 20 dilution, and all but two sera were also positive at 1 : 100. In contrast, only a proportion of the sera contained detectable antibodies to the other EBNAs, and many of these were only detected at the higher serum concentration. Relative to the healthy controls, RA sera as a group showed an increased antibody response to each of EBNAs 2, 3, 4, 5 and 6, the group ofBL sera showed an increased response to EBNAs 3 and 4 and to a lesser extent to EBNA 6, and the NPC sera showed an increased response to EBNAs 3 and 6 but a decreased response to EBNA 2.
Antibodies to LMP and EBNAs in other diseases
Smaller numbers of sera from patients with AIDS-related diseases were tested at a single dilution (1:20) for antibodies to all the EBV latent antigens (Table 5) . Sera from patients with AIDS and PGL showed a pattern of antibody response that could not be distinguished from that of healthy seropositive sera. From the limited number of sera studied, it appears that homosexual controls and patients with Kaposi's sarcoma may have an unusually poor antibody response to EBNA 5.
DISCUSSION
The data presented here, obtained with a new, sensitive and specific assay, demonstrate unequivocally that a humoral response can be mounted to LMP in man. Furthermore, this antibody response was detected for the first time in a proportion of healthy individuals, and was shown to be elevated in patients with BL, NPC and RA. Previous studies using ELISAs incorporating short synthetic LMP peptides (Modrow & Wolf, 1986; Dillner et al., 1987) , have indicated the existence of antibodies to LMP in patients with BL and NPC, but it was not formally shown that the human anti-peptide antibodies actually reacted with LMP itself, and these assays were unable to detect anti-peptide antibodies in healthy sera. The present results suggest that the original ELISAs did, indeed, detect a true anti-LMP response, although it is not clear why they failed to detect antibodies in healthy sera. It may be that this is simply a result of limited sensitivity of the ELISAs using synthetic peptides. Alternatively, it might be argued that BL and NPC patients, but not healthy EBV-seropositive individuals, selectively mount an antibody response to certain epitopes of LMP. This latter possibility would be analogous to the situation apparent for EBNA 2 (discussed below), but it is unlikely to be the case with LMP since each of the four different peptides which were employed as antigens in the ELISAs gave similar results.
The marked increase in the levels of anti-LMP antibodies in BL and NPC patients cannot be attributed simply to increased antigen load as a result of EBV-carrying tumours expressing the antigens. All BL turnouts and at least half of NPC tumours have down-regulated LMP and it is therefore not detectable (Rowe et al., 1987b; Young et al., 1988) . Moreover, two NPC sera were tested for which the tumour biopsy cells were also available; one tumour expressed high levels of LMP, but the serum from the same patient lacked detectable antibodies to LMP, whereas the other tumour lacked detectable LMP and the corresponding serum contained a high titre of antibodies to LMP (M. Rowe, R. F~hreus & B. Kallin; unpublished data) .
It is possible that the elevated anti-LMP response in BL, NPC and RA is a consequence of impaired EBV-specific cytotoxic T cell immunity, which controls the numbers of EBV-infected normal B cells (Gaston et al., 1985; Moss et al., 1983; Whittle et al., 1984) . In this regard it is interesting that the healthy donor ST who showed an exceptionally strong anti-LMP response in the IPIB assay in the present study (Table 3) , has a deficient EBV-specific cytotoxic T cell response (Bejarano et al., 1987) . Affinity-purified human anti-LMP antibodies (see Fig. 2 ) were found to be unreactive with the surface of viable LMP-positive cells in fluorescence tests (data not shown), suggesting that the antibody response is predominantly mounted to epitopes on LMP that are only exposed after cell death. Thus, the anti-LMP response is unlikely to be involved in the immune control of EBV-infected cells, but rather may be a consequence of increased antigen load in the form of increased numbers of EBV-infected normal B cells arising from inefficient T cell control of such cells.
In contrast to the response to LMP, the humoral response to the other six latent EBV proteins, EBNAs 1 to 6, showed less marked differences between the different disease groups studied. Nevertheless, RA sera as a group demonstrated an increased antibody response to EBNAs 2, 3, 4, 5 and 6 compared with healthy control sera, BL sera demonstrated an increased antibody response to EBNAs 3 and 4, and N PC sera demonstrated an increased response to EBNAs 3 and 6 but surprisingly showed reduced titres of antibodies to EBNA 2. As with the humoral response to LMP, the altered response to EBNAs 2 to 6 in BL and NPC cannot be explained in terms of the antigen load of the tumour cells themselves; all of these EBNAs appear to be down-regulated in these turnouts (Rowe et al., 1987b; Rowe & Gregory, 1988; Young et al., 1988) .
Our data on antibody responses to EBNA 2, and particularly the observation that NPC sera showed reduced titres of these antibodies, warrant further comment. As can be seen in Table 6 , our data are in broad agreement with the results reported by Sculley et al. (1986) , who also employed an immunoblotting assay, but they are apparently at variance with results obtained from immunofluorescence assays with EBV-negative cells expressing EBNA 2 following gene transfer Seigneurin et al., 1987) . Both of these fluorescence studies reported an increased incidence of EBNA 2-reactive sera in BL and NPC relative to healthy controls. However, it should be noted that the proportions of positive sera found among healthy controls (1987) .
t IPIB results obtained at two dilutions of sera.
Results of ELISAs incorporating one of two short synthetic peptides (pep115 and pep116) corresponding to EBNA 2 sequences.
§ Only four sera were tested, three of which were positive.
in these studies were just 24~ and 8~ respectively, which is considerably less than the 76~ positive found by immunoblotting in the present work. Henle et al. (1987) , using an immunofluorescence test similar to that of Dillner et al. (1987) and Seigneurin et al. (1987) , demonstrated the presence of anti-EBNA 2 antibodies in 71 ~ of healthy EBV-immune controls, but neither NPC nor BL sera were included in their study. The different results obtained with NPC and BL sera with the two types of assay are not due simply to differences in sensitivity, since the immunoblotting assays actually detected a decreased anti-EBNA 2 response in NPC sera, which is in contrast to the increased incidence of antibodies reported using immunofluorescence tests. This suggests the possibility that different epitopes were detected in each assay system, and that differential antibody responses may be mounted to each epitope in individual groups of patients. Support for this interpretation comes from the results of a third type of assay, ELISAs incorporating peptides corresponding to sequences within the EBNA 2 protein . Thus, as shown in Table 6 , NPC patients appear to mount a selective response to an epitope on peptide 116 corresponding to an internal hydrophilic, proline-rich sequence of the EBNA 2 protein. Although the significance of this phenomenon is not clear, it may well explain the discrepancy between our results and the published data on anti-EBNA 2 antibody responses in NPC.
In conclusion, determination of the antibody response to each of the individual transformation-associated EBV antigens, particularly LMP, has revealed some diseaseassociated differences in patients BL, NPC and RA. The cause of these differences is not known, but further studies to determine whether there is a correlation between these antibody responses and the numbers of EBV-infected B cells in the blood may prove informative.
